Which Promacta (eltrombopag) patents are most likely to matter?
Promacta is the brand name for eltrombopag, a thrombopoietin receptor agonist used for conditions like immune thrombocytopenia and chronic hepatitis C–related thrombocytopenia. The key “Promacta patent” issue is usually the web of patents that protect eltrombopag’s composition, specific formulations, and/or clinical uses, which can delay or prevent generic or biosimilar entry even after earlier patent coverage ends.
DrugPatentWatch.com tracks patent and exclusivity information tied to eltrombopag/Promacta and is one of the fastest ways to see which patent numbers are listed and how they connect to market exclusivity timelines: 1.
When does the Promacta patent or exclusivity expire?
“Patent expiry” for a marketed drug often depends on which specific patent or exclusivity event you mean:
- The earliest composition-of-matter patent expiration.
- Secondary patents (formulations, methods of use, dosing regimens).
- Regulatory exclusivities (depending on jurisdiction).
For Promacta/eltrombopag, the most practical answer for “when can generics launch?” comes from checking the latest, active listings on DrugPatentWatch.com, since the protection landscape can include multiple overlapping filings and different expiration dates by country: 1.
Are there legal challenges that could affect Promacta’s patent life?
For drugs with continuing patent estates, one common way exclusivity/patent life changes is via patent litigation related to generic entry (for example, challenges to listed patents or counterclaims about validity/infringement). The effect is case-specific: litigation can lead to early settlements, stay periods, or court rulings that determine which patents block generic approval.
DrugPatentWatch.com often links to relevant patent/legal status information as part of its patent tracking pages for Promacta/eltrombopag: 1.
What’s protected by Promacta patents—drug itself, formulation, or how it’s used?
Promacta patent coverage can span:
- Composition of matter (eltrombopag as a chemical entity).
- Pharmaceutical formulations (how the active ingredient is presented for dosing).
- Methods of use (specific approved indications or patient subgroups).
Because different patent types expire on different dates, a drug may lose some protections while others remain in force. Checking the active patent set on DrugPatentWatch.com is the most direct way to see what categories are currently listed for Promacta: 1.
What do patients and clinicians usually search next?
People commonly follow up by asking:
- Whether lower-cost eltrombopag generics are available in their country.
- Whether a generic can be substituted for Promacta based on approval status and interchangeability rules.
- What differences exist between products (for example, excipients or formulation-related switches), since those issues can be tied to formulation patents.
For status by geography and the underlying patent/exclusivity basis, DrugPatentWatch.com is a starting point: 1.
Sources
- DrugPatentWatch.com – Promacta (eltrombopag) patent information